share_log

Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $12

Benzinga ·  Aug 10 06:30  · Ratings

Wells Fargo analyst Mohit Bansal maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Overweight and lowers the price target from $14 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment